A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers
Recruiting now NCT06085781
Run by University Health Network, Toronto · for 18 and older · All sexes
What this study is about
The purpose of this study is to explore biomarker development in patients with newly diagnosed Head and neck squamous cell carcinoma (HNSCC) receiving curative therapy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Age >/= 18 years
- Histologically proven Head and Neck Squamous Cell carcinoma
- Primary or nodal disease > 3cm for biomarker imaging
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Planned for curative surgery or (chemo)radiotherapy
- Willingness to undergo repeat MRI imaging
- Able to receive and understand verbal and written information regarding study and able to give written informed consent
- Adequate renal function: Calculated creatinine clearance >/= 30ml/min
- Be able to lie comfortably on back for 1 hour
🚫 You may not be able to join if…
- As judged by investigator evidence of systemic disease that makes unsuitable for study
- Contra-indication for serial MRI scans
- Previous solid tumor treated within last 5 years
- Pregnancy
- History of gadolinium contrast allergy
- Non-reversible clotting abnormality
Where this trial is running
- Princess Margaret Cancer Center, Toronto, Ontario, Canada
Who to contact
Andrew McPartlin · 416-946-4501 · andrew.mcpartlin@uhn.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06085781.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.